The FDA-Approved Oral Drug Nitazoxanide Amplifies Host Antiviral Responses and Inhibits Ebola Virus

Here, we show that the US Food and Drug Administration-approved oral drug nitazoxanide (NTZ) broadly amplifies the host innate immune response to viruses and inhibits Ebola virus (EBOV) replication. We find that NTZ enhances retinoic-acid-inducible protein I (RIG-I)-like-receptor, mitochondrial anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Jasenosky, Luke D., Cadena, Cristhian, Mire, Chad E., Borisevich, Viktoriya, Haridas, Viraga, Ranjbar, Shahin, Nambu, Aya, Bavari, Sina, Soloveva, Veronica, Sadukhan, Supriya, Cassell, Gail H., Geisbert, Thomas W., Hur, Sun, Goldfeld, Anne E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6831822/
https://www.ncbi.nlm.nih.gov/pubmed/31402258
http://dx.doi.org/10.1016/j.isci.2019.07.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6831822/
https://www.ncbi.nlm.nih.gov/pubmed/31402258
http://dx.doi.org/10.1016/j.isci.2019.07.003

Ejemplares similares